glp 1 facts GLP-1 Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity GLP-1 Natural Booster – BloomMD

The semaglutide market will be supported by rising diagnosis of type 2 diabetes requiring early-stage incretin therapy, strong clinical preference for twice-daily and once-weekly formulations among patients needing weight management assistance, growing adoption due to favorable glycemic control outcomes in overweight adults, increasing use in combination therapy for individuals with uncontrolled HbA1c levels, expanding access through reimbursement programs across developing regions and broader physician familiarity with long-established molecules in this class

[DOI] [PubMed] [Google Scholar] 69.ONeil PM, et al

However, up to 50% of patients may remain asymptomatic

137.Sharma G

J Endocrinol (2009) 202(3):4319

Studies show that people with obesity and IBD are at higher risk of developing additional health issues, lending weight to exploring this intersection (3)